Global Blood Plasma Derivatives Market Size study & Forecast, by Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Others), by Application (Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, Von Willebrand'S Disease,

Global Blood Plasma Derivatives Market Size study & Forecast, by Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Others), by Application (Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, Von Willebrand'S Disease, Other Application), by End User (Hospitals, Clinics, Others) and Regional Analysis, 2023-2030

Global Blood Plasma Derivatives Market is valued at approximately USD 43650.9 million in 2022 and is anticipated to grow with a healthy growth rate of more than 9.4% over the forecast period 2023-2030. The blood plasma derivatives market refers to the segment of the pharmaceutical industry that involves the collection, processing, and commercialization of therapeutic products derived from human blood plasma. These derivatives are obtained through a complex manufacturing process that includes fractionation, purification, and sterilization to isolate and extract specific proteins, antibodies, and other bioactive substances found in blood plasma. These products are used for various therapeutic purposes, including treating immune disorders, coagulation disorders, and certain genetic diseases. The blood plasma derivatives market is being driven by factors such as the increasing geriatric population that are more susceptible to developing infectious diseases and the Increasing prevalence of chronic diseases.

Blood plasma derivatives play a crucial role in the treatment of various medical conditions and provide therapeutic options for patients with immune deficiencies, coagulation disorders, and other diseases. According to the International Diabetes Federation (IDF), diabetes can afflict 537 million adults globally in 2021, with one in ten experiencing other diabetes. Furthermore, geriatric, and obese populations are predisposed to chronic diseases. According to the World Bank Group, the world old population was 727 million in 2020, and it is predicted to treble over the next three decades, reaching 1.5 billion in 2050.Thus, the growing prevalence of chronic disease and the growing aging population fueling the growth of the market. In addition, increasing awareness & diagnosis of rare diseases and technological advancements in plasma fractionation. However, strict regulatory compliances may hinder the growth of the market throughout the forecast period of 2023-2030.

The key regions considered for the Global Blood Plasma Derivatives Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the well-developed healthcare infrastructure, including hospitals, clinics, and diagnostic centers. These facilities have advanced capabilities for blood plasma collection, processing, and manufacturing of derivatives, leading to a robust market for plasma-based products. North America is also considered the fastest growing region during the forecasted period due to the high demand for plasma-derived products and reimbursement systems.

Major market player included in this report are:
Baxter International Inc.
Bayer AG
CSL Limited
Fusion Health Care Pvt. Ltd.
Grifols S.A.
Kedrion S.p.A.
LFB S.A.
Octapharma AG
Sanofi S.A.
Takeda Pharmaceutical Company Limited

Recent Developments in the Market:
In March 2020, Grifols collaborates with the United States Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration (FDA) and other Federal public health agencies to collect plasma from convalescent COVID-19 patients, process this specific plasma into a hyperimmune globulin and support the necessary preclinical and clinical studies to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can successfully be used to treat COVID-19 disease. Grifols will volunteer its expertise and resources in the areas of plasma collection using its network of FDA-approved plasma donor centers; test and qualify donors in conjunction with other health agencies; process plasma into hyperimmune globulin in its purpose-built facility in Clayton, North Carolina, for the isolated processing of immune globulins to treat emerging infectious diseases.

Global Blood Plasma Derivatives Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered -, Type, Application, End User, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
Albumin
Factor VIII
Factor IX
Immunoglobulin
Hyperimmune Globulin
Others

By Application:
Hemophilia
Hypogammaglobulinemia
Immunodeficiency Diseases
Von Willebrand'S Disease
Other Application

By End User:
Hospitals
Clinics
Others End User

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies
Baxter International Inc.
Bayer AG
CSL Limited
Fusion Health Care Pvt. Ltd.
Grifols S.A.
Kedrion S.p.A.
LFB S.A.
Octapharma AG
Sanofi S.A.
Takeda Pharmaceutical Company Limited

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.